Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma

Stacey Stauffer,Jacob S. Roth,Edjay R. Hernandez,Joshua T. Kowalczyk,Nancy E. Sealover,Katie E. Hebron,Amy James,Kristine A. Isanogle,Lisa A. Riffle,Lilia Ileva,Xiaoling Luo,Jin-Qiu Chen,Noemi Kedei,Robert L. Kortum,Haiyan Lei,Jack F. Shern,Joseph D. Kalen,Elijah F. Edmondson,Matthew D. Hall,Simone Difilippantonio,Carol J. Thiele,Marielle E. Yohe

DOI: https://doi.org/10.3390/cancers16132320

2024-06-26

Cancers

Abstract:Activating mutations in the RAS/MAPK pathway are observed in relapsed neuroblastoma. Preclinical studies indicate that these tumors have an increased sensitivity to inhibitors of the RAS/MAPK pathway, such as MEK inhibitors. MEK inhibitors do not induce durable responses as single agents, indicating a need to identify synergistic combinations of targeted agents to provide therapeutic benefit. We previously showed preclinical therapeutic synergy between a MEK inhibitor, trametinib, and a monoclonal antibody specific for IGF1R, ganitumab in RAS-mutated rhabdomyosarcoma. Neuroblastoma cells, like rhabdomyosarcoma cells, are sensitive to the inhibition of the RAS/MAPK and IGF1R/AKT/mTOR pathways. We hypothesized that the combination of trametinib and ganitumab would be effective in RAS-mutated neuroblastoma. In this study, trametinib and ganitumab synergistically suppressed neuroblastoma cell proliferation and induced apoptosis in cell culture. We also observed a delay in tumor initiation and prolongation of survival in heterotopic and orthotopic xenograft models treated with trametinib and ganitumab. However, the growth of both primary and metastatic tumors was observed in animals receiving the combination of trametinib and ganitumab. Therefore, more preclinical work is necessary before testing this combination in patients with relapsed or refractory RAS-mutated neuroblastoma.

oncology

What problem does this paper attempt to address?

The problem this paper attempts to address is the treatment challenge of recurrent neuroblastoma. Specifically, patients with recurrent neuroblastoma have poor prognoses, and there is currently a lack of effective treatment methods. Some recurrent neuroblastomas have activating mutations in the RAS/MAPK pathway, making these tumors sensitive to RAS/MAPK pathway inhibitors. However, single MEK inhibitors or IGF1R inhibitors have limited efficacy in neuroblastoma models. Therefore, researchers hypothesized that the combined use of MEK inhibitor (trametinib) and IGF1R inhibitor (ganitumab) might produce a synergistic effect in RAS-mutant neuroblastomas, thereby improving treatment outcomes.

To test this hypothesis, researchers evaluated the efficacy of the combined use of trametinib and ganitumab in both in vitro and in vivo experiments. The study results showed that this combination therapy significantly inhibited the proliferation of RAS-mutant neuroblastoma cells and induced apoptosis. However, although the combination therapy delayed tumor onset and extended survival in some models, it failed to completely prevent the growth of primary and metastatic tumors. Therefore, researchers believe that further preclinical studies are needed before applying this combination therapy to clinical trials.